Pictet Asset Management (Switzerland)’s Haemonetics HAE Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$489K	Sell	5,746 -561	-9%	-$47.4K	﹤0.01%	1252
2023 Q1	$522K	Hold	6,307	–	–	﹤0.01%	1233
2022 Q4	$496K	Buy	6,307 +2,532	+67%	+$204K	﹤0.01%	1250
2022 Q3	$279K	Hold	3,775	–	–	﹤0.01%	1268
2022 Q2	$246K	Hold	3,775	–	–	﹤0.01%	1356
2022 Q1	$239K	Hold	3,775	–	–	﹤0.01%	1472
2021 Q4	$200K	Hold	3,775	–	–	﹤0.01%	1604
2021 Q3	$266K	Buy	+3,775	New	+$238K	﹤0.01%	1467

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s HAE Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) reduced its Haemonetics (HAE) stake by 8.9% in Q2 2023, selling an estimated $47.4K and leaving 5,746 shares worth $489K. The position accounts for ﹤0.01% of the portfolio, ranked #1252.

Pictet Asset Management (Switzerland) first reported a position in HAE in Q3 2021 and has held it in 8 quarters since. The position peaked at $522K in Q1 2023. 296 funds tracked by Wall St. Rank hold HAE as of Q2 2023.

Pictet Asset Management (Switzerland) held 5,746 shares of Haemonetics worth $489K as of Q2 2023.
Pictet Asset Management (Switzerland) sold 561 Haemonetics shares in Q2 2023, an estimated $47.4K.
Haemonetics made up ﹤0.01% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #1252 holding.
Pictet Asset Management (Switzerland) first reported a position in Haemonetics in Q3 2021 and has held it in 8 quarters since.
Pictet Asset Management (Switzerland)'s Haemonetics position peaked at $522K in Q1 2023.
296 funds tracked by Wall St. Rank held Haemonetics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.